4篇
您的检索式：作者名="J.Metselaar"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Similar liver transplantation survival with selected cardiac death donors and brain death donors显示文摘 | J.Dubbeld H.Hoekstra W.Farid J.Ringers R. J.Porte H. J.Metselaar A. G.Baranski G.Kazemier A. P.van den Berg B.van Hoek | 2010 | Br J Surg2010，，5： | 2 |
| 2 | Persistent fatigue in liver transplant recipients: a two‐year follow‐up study显示文摘 | Berbke T.J.Van Ginneken Rita J.G.Van Den Berg‐Emons AnnaVan Der Windt Huug W.Tilanus Herold J.Metselaar Henk J.Stam GeertKazemier | 2010 | Clinical Transplantation2010，，1： | 1 |
| 3 | Combined antiviral activity of interferon-α and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing显示文摘The current standard interferon-alpha(IFN-α)-based therapy for chronic hepatitis C virus(HCV) infection is only effective in approximately half of the patients, prompting the need for alternative treatments. RNA interference(RNAi) represents novel approach to combat HCV by sequence-specific targeting of viral or host factors involved in infection. Monotherapy of RNAi, however, may lead to therapeutic resistance by mutational escape of the virus. Here, we proposed that combining lentiviral vector-mediated RNAi and IFN-α could be more effective and avoid therapeutic resistance. In this study, we found that IFN-α treatment did not interfere with RNAi-mediated gene silencing. RNAi and IFN-α act independently on HCV replication showing combined antiviral activity when used simultaneously or sequentially. Transduction ofmouse hepatocytes in vivo and in vitro was not effected by IFN-α treatment. In conclusion, RNAi and IFN-α can be effectively combined without crossinterference and may represent a promising combinational strategy for the treatment of hepatitis c. | Qiuwei Pan Scot D.Henry Herold J.Metselaar Bob Scholte Jaap Kwekkeboom Hugo W.Tilanus Harry L.A.Janssen Auc J.W.van der Laan | 2016 | 世界最新医学信息文摘2016，16，11： | 0 |
| 4 | Randomized Trial of Ciclosporin with 2-h Monitoring vs.Tacrolimus with Trough Monitoring in Liver Transplantation:DELTA Study显示文摘Background and Aims:Previous trials comparing cyclosporine and tacrolimus after liver transplantation(LT)showed conflicting results.Most used trough monitoring for cyclosporine(C0),leading to less accurate dosing than with 2-h monitoring(C2).Only one larger trial compared C2 with tacrolimus based on trough level(T0)after LT,with similar treated biopsy-proven acute rejection(tBPAR)and graft loss,while a smaller trial had less tBPAR with C2 compared to T0.Therefore,it is still unclear which calcineurin inhibitor is preferred after LT.We aimed to demonstrate superior efficacy(tBPAR),tolerability,and safety of C2 or T0 after first LT.Methods:Patients after first LT were randomized to C2 or T0.tBPAR,patient-and graft survival,safety and tolerability were the main endpoints,with analysis by Fisher test,Kaplan-Meier survival analysis and log-rank test.Results:In intention-totreat analysis 84 patients on C2 and 85 on T0 were included.Cumulative incidence of tBPAR C2 vs.T0 was 17.7%vs.8.4%at 3 months(p=0.104),and 21.9%vs.9.7%at 6 and 12 months(p=0.049).One-year cumulative mortality C2 vs.T0 was 15.5%vs.5.9%(p=0.049)and graft loss 23.8%vs.9.4%(p=0.015).Serum triglyceride and LDL-cholesterol was lower with T0 than with C2.Incidence of diarrhea in T0 vs,C2 was 64%vs.31%(p≤0.001),with no other differences in safety and tolerability.Conclusions:In the first year after LT immunosuppression with T0 leads to less tBPAR and better patient-/re-transplant-free survival as compared to C2. | Bastian N.Ruijter Akin Inderson Aad Pvan den Berg Herold J.Metselaar Jeroen Dubbeld Maarten E.Tushuizen Robert J.Porte Wojciech Polak Danny van der Helm Marjolein van Reeven Mar Rodriguez-Girondo Bart van Hoek | 2023 | Journal of Clinical and Translational Hepatology2023，11，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员